Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study [0.03%]
巴利昔单抗与瑞特西单抗治疗重度斑秃疗效和安全性的比较：单中心回顾性研究
Francesco D&#x;Oria,Sara Di Giulio,Luciano Ibba et al.
Francesco D&#x;Oria et al.
Introduction: Baricitinib and ritlecitinib are approved targeted therapies for severe alopecia areata (AA), but direct comparative real-world data remain limited. This monocentric retrospective study evaluated the treatme...
Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis [0.03%]
针对中重度斑块状银屑病成人患者的risankizumab与icotropilimab匹配调整的间接比较
Jeffrey Crowley,Eingun James Song,Linda Stein-Gold et al.
Jeffrey Crowley et al.
Introduction: Risankizumab (RZB) is an approved injectable IL-23 inhibitor with demonstrated high levels of skin clearance, and icotrokinra (ICO) is an oral IL-23 receptor blocker recently approved for the treatment of mo...
Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival [0.03%]
中至重度银屑病免疫生物制剂治疗依从性不足对药物生存期影响的回顾队列研究
Luciana A Ribeiro,Patrícia S Kurizky,Rodrigo R de Sena et al.
Luciana A Ribeiro et al.
Introduction: Evaluating psoriasis care in Brazil, a country characterized by its vast geographical expanse, may provide valuable lessons for healthcare systems globally. National research has revealed that individuals re...
Efficacy and Safety of Rituximab in Pemphigus Foliaceus: A Systematic Review and Meta-analysis [0.03%]
利妥昔单抗治疗落叶型天疱疮有效性和安全性的系统评价和 meta 分析
Camille Kieffer,Vivien Hebert,Pascal Joly et al.
Camille Kieffer et al.
Introduction: While rituximab has been approved for moderate-to-severe pemphigus vulgaris, data on pemphigus foliaceus (PF) remain limited because of the small number of patients included in therapeutic trials. However, c...
Modified Delphi Consensus Recommendations for the Management of Psoriasis in Asia-Pacific [0.03%]
亚太地区银屑病诊疗的德尔菲法共识修改意见
Yoo Sang Baek,Siew Eng Choon,Peter Anthony Foley et al.
Yoo Sang Baek et al.
Introduction: Psoriasis imposes a substantial clinical and quality-of-life burden across the Asia-Pacific (APAC) region. Despite advances in systemic therapies, variability in disease severity classification, assessment t...
Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week 4 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase III Trials [0.03%]
钙泊三醇/倍他米松复方制剂治疗轻中度斑块状银屑病4周快速起效：两项3期临床研究的事后分析
Maria Esposito,Juan Manuel Morón-Ocaña,Aditya K Gupta et al.
Maria Esposito et al.
Introduction: Topical therapy plays an essential role in psoriasis management. However, lack of rapid improvement may negatively impact adherence. The calcipotriol and betamethasone dipropionate (CAL/BDP) cream based on p...
Kenan Kherallah,Claire S Chung,Raveena Ghanshani et al.
Kenan Kherallah et al.
Sleep disturbance is increasingly recognized as an important dimension of morbidity in chronic spontaneous urticaria (CSU), yet existing evidence remains fragmented across clinical, psychosocial, and physiologic domains. We conducted a syst...
Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy [0.03%]
生物制剂bimekizumab治疗慢性斑块状银屑病真实世界研究：为期两年的疗效和安全性分析
Zeno Fratton,Stefano Bighetti,Luca Bettolini et al.
Zeno Fratton et al.
Introduction: Bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, has demonstrated high efficacy in clinical trials for moderate-to-severe plaque psoriasis. However, real-world evidence regarding its long-term ...
Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis [0.03%]
阿布昔替尼治疗特应性皮炎达到早期且完全/几乎完全的皮肤清除以及无瘙痒状态：来自III期临床研究的事后分析
Stephen Weidinger,Kristian Reich,Naiem Issa et al.
Stephen Weidinger et al.
Introduction: Abrocitinib, a Janus kinase inhibitor, is approved for patients with moderate-to-severe atopic dermatitis. Methods: This ...
Letter to the Editor Regarding "Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis" [0.03%]
关于《特拉鲁单抗和莱比吉珠单抗治疗中至重度特应性皮炎患者的长期疗效锚定匹配调整法间接比较》的读者来信
Kim Rand,Kurt Gebauer,Yousef Binamer et al.
Kim Rand et al.